Cooley has participated in more than 380 offerings since 2000, raising more than $35.7 billion. Following are some recent representative offerings.
Completed IPOs
| Issuer |
Offering Amount
(in millions) |
Date |
| Gladstone Land Corporation |
$45.6 |
January 2013 |
| LipoScience, Inc. |
$51.8 |
January 2013 |
| Ruckus Wireless |
$126.0 |
November 2012 |
| Ambarella, Inc.* |
$41.4 |
October 2012 |
| Regulus Therapeutics Inc. |
$50.9 |
October 2012 |
| LifeLock, Inc.* |
$141.3 |
October 2012 |
| Qualys, Inc.* |
$90.9 |
September 2012 |
| Peregrine Semiconductor Corporation* |
$77.0 |
August 2012 |
| Hyperion Therapeutics, Inc.* |
$57.5 |
July 2012 |
| ServiceNow, Inc.* |
$241.2 |
June 2012 |
| Enphase Energy, Inc. |
$53.8 |
March 2012 |
| Millenial Media, Inc. |
$132.6 |
March 2012 |
| Vocera Communications, Inc.* |
$93.6 |
March 2012 |
| Yelp |
$107.3 |
March 2012 |
| Proto Labs, Inc.* |
$68.8 |
February 2012 |
| Zynga Inc. |
$1000.0 |
December 2011 |
| NewLink Genetics Corporation |
$43.4 |
November 2011 |
| Horizon Pharma, Inc. |
$49.5 |
July 2011 |
| Tangoe, Inc.* |
$87.7 |
July 2011 |
| LinkedIn Corporation* |
$352.8 |
May 2011 |
| AcelRx Pharmaceuticals, Inc. |
$40.0 |
February 2011 |
| NeoPhotonics Corporation |
$94.9 |
February 2011 |
| Epocrates, Inc. |
$98.6 |
February 2011 |
| Anacor Pharmaceuticals, Inc. |
$60 |
November 2010 |
| Trius Therapeutics, Inc. |
$50 |
August 2010 |
| BroadSoft, Inc. |
$67.5 |
June 2010 |
| Convio, Inc.* |
$46.2 |
April 2010 |
| Calix* |
$82.3 |
March 2010 |
| QuinStreet |
$150 |
February 2010 |
| Rosetta Stone* |
$112.5 |
April 2009 |
| CardioNet |
$81.0 |
March 2008 |
| Entropic Communications, Inc. |
$48.0 |
December 2007 |
| ARYx Therapeutics, Inc. |
$50.0 |
November 2007 |
| Genoptix, Inc. |
$85.0 |
October 2007 |
| Dupont Fabros Technology, Inc. |
$640.5 |
October 2007 |
| Compellent Technologies, Inc. |
$81.0 |
October 2007 |
| Infinera Corporation* |
$182.0 |
June 2007 |
| Jazz Pharmaceuticals |
$108.0 |
May 2007 |
| Cavium Networks Inc. |
$91.1 |
May 2007 |
| Veraz Networks Inc. |
$72.0 |
March 2007 |
| Affymax, Inc. |
$92.5 |
December 2006 |
| Hansen Medical, Inc. |
$75.0 |
November 2006 |
| DivX, Inc. |
$145.6 |
September 2006 |
| Replidyne, Inc. |
$45.0 |
June 2006 |
| Acquicor Technology, Inc. |
$150.0 |
March 2006 |
| Alexza Pharmaceuticals, Inc. |
$44.0 |
March 2006 |
| Cardica, Inc. |
$35.0 |
February 2006 |
| SGX Pharmaceuticals, Inc. |
$24.0 |
January 2006 |
| Highbury Financial, Inc.* |
$40.4 |
January 2006 |
*Represented the underwriters
Completed Follow-On Offerings
| Issuer |
Offering Amount
(in millions) |
Date |
| NewLink Genetics Corporation |
$45.6 |
January 2013 |
| Anthera Pharmaceuticals, Inc* |
$46.0 |
January 2013 |
| Trius Therapeutics, Inc. |
$11.3 |
January 2013 |
| Trius Therapeutics, Inc. |
$23.1 |
January 2013 |
| Onyx Pharmaceuticals |
$358.6 |
January 2013 |
| InterMune, Inc.* |
$153.7 |
January 2013 |
| AcelRx Pharmaceuticals, Inc. |
$41.4 |
December 2012 |
| DURECT Corporation* |
$12.6 |
December 2012 |
| NovaBay Pharmaceuticals, Inc. |
$7.4 |
December 2012 |
| Proto Labs, Inc.* |
$128.3 |
November 2012 |
| ServiceNow, Inc.* |
$392.0 |
November 2012 |
| Millennial Media, Inc. |
$141.5 |
October 2012 |
| Xoma Corporation |
$40.0 |
October 2012 |
| MannKind Corporation |
$92.0 |
October 2012 |
| ImmunoCellular Therapeutics, Ltd |
$21.0 |
October 2012 |
| Anacor Pharmaceuticals, Inc. |
$27.6 |
October 2012 |
| Geron |
$50.0 |
October 2012 |
| Rigel Pharmaceuticals, Inc. |
$149.5 |
October 2012 |
| Horizon Pharma, Inc. |
$81.1 |
October 2012 |
| Vocera Communications, Inc.* |
$138.7 |
September 2012 |
| AcelRx Pharmaceuticals, Inc. |
$7.5 |
September 2012 |
| Exelixis, Inc. |
$146.6 |
August 2012 |
| MAP Pharmaceuticals, Inc.* |
$59.8 |
August 2012 |
| XenoPort, Inc. |
$46.0 |
August 2012 |
| Anthera Pharmaceuticals, Inc.* |
$38.0 |
July 2012 |
| Arena Pharmaceuticals, Inc. |
$69.6 |
May 2012 |
| PROLOR Biotech, Inc.* |
$37.4 |
May 2012 |
| Dynavax Technologies Corporation |
$55.0 |
May 2012 |
| Tangoe, Inc.* |
$148.0 |
March 2012 |
| Zynga Inc. |
$593.0 |
March 2012 |
| Amylin Pharmaceuticals, Inc. |
$210.5 |
March 2012 |
| Jazz Pharmaceuticals Public Company Limited |
$390.7 |
March 2012 |
| Arena Pharmaceuticals, Inc. |
$24.9 |
March 2012 |
| Alexza Pharmaceuticals, Inc. |
$22.0 |
February 2012 |
| Exelixis, Inc. |
$69.6 |
February 2012 |
| Cardica, Inc. |
$15.0 |
February 2012 |
| MannKind Corporation |
$86.2 |
February 2012 |
| Ardea Biosciences, Inc. |
$166.2 |
February 2012 |
| Trius Therapeutics, Inc. |
$45.2 |
January 2012 |
| ZIOPHARM Oncology, Inc. |
$62.0 |
January 2012 |
| Sequenom Inc. |
$62.0 |
January 2012 |
| Neurocrine Biosciences, Inc. |
$77.0 |
January 2012 |
| Vical, Inc. |
$9.9 |
January 2012 |
| LinkedIn Corporation* |
$714.4 |
November 2011 |
| Cadence Pharmaceuticals* |
$81.8 |
November 2011 |
| Dynavax Technology |
$69.4 |
November 2011 |
| Gladstone Capital Corporation |
$38.5 |
November 2011 |
| InterMune, Inc.* |
$96.0 |
September 2011 |
| GTx, Inc. |
$47.5 |
June 2011 |
| Cerus Corporation |
$20.0 |
June 2011 |
| Rigel Pharmaceuticals, Inc. |
$150.0 |
May 2011 |
| Medicinova, Inc. |
$15.0 |
May 2011 |
| Alexza Pharmaceuticals |
$16.1 |
May 2011 |
| Arca Biopharma, Inc. |
$3.0 |
April 2011 |
| Iridium Communications, Inc. |
$32.9 |
March 2011 |
| Medicinova, Inc. |
$8.3 |
March 2011 |
| Affymax, Inc. |
$47.0 |
March 2011 |
| Exelexis, Inc. |
$189.8 |
March 2011 |
| Opko Health, Inc.* |
$110.2 |
March 2011 |
| Limelight Networks* |
$81.7 |
February 2011 |
| Optimer Pharmaceuticals, Inc. |
$77.6 |
February 2011 |
| ZIOPHARM Oncology, Inc.* |
$55.2 |
February 2011 |
| Seattle Genetics, Inc. |
$178.3 |
February 2011 |
| Corcept Therapeutics Incorporated* |
$44.9 |
January 2011 |
| Ardea Biosciences, Inc. |
$82.2 |
January 2011 |
| Nektar Therapeutics* |
$225.2 |
January 2011 |
| Quidel Corporation* |
$60.5 |
January 2011 |
| BroadSoft, Inc. |
$116.6 |
December 2010 |
| Aastrom Biosciences, Inc.* |
$22.5 |
December 2010 |
| XenoPort Inc. |
$28.6 |
December 2010 |
| Sequenom Inc. |
$96.6 |
December 2010 |
| Somaxon Pharmaceuticals, Inc.* |
$26.0 |
November 2010 |
| Micromet, Inc. |
$70.8 |
November 2010 |
| Cerus Corporation |
$21.0 |
November 2010 |
| Cadenece Pharmaceuticals* |
$100.0 |
November 2010 |
| Dynavax Technologies |
$45.0 |
October 2010 |
| GTx, Inc. |
$40.0 |
October 2010 |
| Anadys Pharmaceuticals, Inc. |
$25.0 |
October 2010 |
| Cytori Therapeutics Inc.* |
$20.7 |
October 2010 |
| Sunesis Pharmaceuticals, Inc. |
$15.5 |
October 2010 |
| Entropic Communications |
$104.3 |
September 2010 |
| Vical, Inc. |
$33.8 |
September 2010 |
| Aspen Technology |
$162.0 |
September 2010 |
| Radiant Systems* |
$91.8 |
September 2010 |
| MannKind Corporation |
$50.0 |
August 2010 |
| Alexza Pharmaceuticals |
$18.0 |
August 2010 |
| Corcept Therapeutics Incorporated* |
$15.0 |
June 2010 |
| Clinical Data |
$27.8 |
June 2010 |
| ZIOPHARM Oncology, Inc.* |
$35 |
May 2010 |
| Anadys Pharmaceuticals, Inc. |
$12.5 |
May 2010 |
| RegeneRx BioPharmaceuticals, Inc. |
$4.7 |
May 2010 |
| Jazz Pharmaceuticals |
$58.5 |
May 2010 |
| Alphatec Holdings* |
$80.0 |
April 2010 |
| Dynavax Technologies Corporation |
$44.0 |
April 2010 |
| Ardea Biosciences |
$70.0 |
April 2010 |
| Somaxon Pharmaceuticals, Inc.* |
$49.5 |
March 2010 |
| Micromet, Inc. |
$70.0 |
March 2010 |
| Neurocrine Biosciences, Inc. |
$20.0 |
March 2010 |
| Optimer Pharmaceuticals |
$46.8 |
February 2010 |
| Senomyx, Inc. |
$20.0 |
February 2010 |
| Art Technology Groups, Inc.* |
$87.5 |
February 2010 |
| AMAG Pharmaceuticals |
$165.9 |
January 2010 |
| InterMune, Inc.* |
$98.7 |
January 2010 |
| Neurocrine Biosciences, Inc. |
$10.0 |
December 2009 |
| Arca Biopharma |
$10.0 |
December 2009 |
| Affymax, Inc. |
$75.0 |
November 2009 |
| Compellent Technologies |
$64.3 |
November 2009 |
| Gladstone Commercial Corporation |
$20.0 |
November 2009 |
| Dynavax Technologies Corporation |
$12.2 |
October 2009 |
| Clinical Data |
$47.4 |
October 2009 |
| Allos Therapeutics |
$99.4 |
October 2009 |
| Verenium Corporation |
$13.5 |
October 2009 |
| RegeneRx BioPharmaceuticals |
$3.7 |
September 2009 |
| Rigel Pharmaceuticals |
$94.3 |
September 2009 |
| NovaBay Pharmaceuticals |
$2.45 |
August 2009 |
| Cerus Corporation |
$13.2 |
August 2009 |
| Seattle Genetics |
$118.3 |
August 2009 |
| Seattle Genetics |
$118.3 |
August 2009 |
| Onyx Pharmaceuticals |
$122.0 |
August 2009 |
| MAP Pharmaceuticals* |
$34.0 |
August 2009 |
| MannKind Corporation |
$47.0 |
August 2009 |
| Micromet, Inc. |
$70.0 |
July 2009 |
| XenoPort Inc. |
$47.5 |
July 2009 |
| Arena Pharmaceuticals |
$52.1 |
July 2009 |
| Phoenix Technologies |
$13.1 |
June 2009 |
| Medivation, Inc. |
$57.8 |
May 2009 |
| Allos Therapeutics |
$48.8 |
March 2009 |
| Intermune* |
$57.2 |
February 2009 |
| Seattle Genetics Inc. |
$55.8 |
January 2009 |
| Sequenom Inc. |
$85.3 |
June 2008 |
| Allos Therapeutics Inc. |
$60.9 |
May 2008 |
| Genoptix Medical Laboratory |
$53.2 |
February 2008 |
| Rigel Pharmaceuticals Inc. |
$127.9 |
January 2008 |
| Gladstone Capital Corporation |
$51.0 |
January 2008 |
| Anesiva |
$45.0 |
December 2007 |
| Progressive Gaming International Corporation |
$50.0 |
November 2007 |
| Cardica, Inc. |
$34.7 |
November 2007 |
| Arena Pharmaceuticals, Inc. |
$109.0 |
November 2007 |
| Infinera Corporation* |
$220.0 |
October 2007 |
| Volcano Corporation |
$113.8 |
October 2007 |
| InterMune, Inc.* |
$68.3 |
September 2007 |
| Exelixis, Inc. |
$89.7 |
September 2007 |
| Onyx Pharmaceuticals |
$184.8 |
June 2007 |
| Cypress Bioscience Inc. |
$72.9 |
June 2007 |
| Syntax-Brillian Corp* |
$147.2 |
May 2007 |
| Sunesis Pharmaceuticals, Inc. |
$21.0 |
May 2007 |
| Omnicell Inc. |
$83.9 |
May 2007 |
| Rigel Pharmaceuticals Inc. |
$48.8 |
May 2007 |
| Pharmacopeia Drug Discovery Inc.* |
$35.0 |
May 2007 |
| Genitope Corporation |
$21.2 |
April 2007 |
| Alexza Pharmaceuticals |
$61.5 |
April 2007 |
| Kosan Biosciences Inc |
$45.5 |
February 2007 |
| Repros Therapeutics* |
$35.8 |
January 2007 |
| Aradigm Corporation |
$31.4 |
January 2007 |
*Represented the underwriters
|